ProKidney Corp. has announced a new Open Market Sale Agreement with Jefferies LLC, enabling the company to offer and sell shares of its Class A common stock, valued up to $200 million, through Jefferies acting as an agent. This agreement is part of ProKidney's "at the market" program and will be conducted under the company's shelf registration statement on Form S-3. The sales will be made in accordance with a prospectus supplement filed by the company, allowing for periodic sales at the company's discretion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.